Ob/Gyn Medical News about breast cancer;tamoxifen treatment;MUC1-induced alterations

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment
Proceedings of the National Academy of Sciences of the United States of America, 04/17/09

Pitroda SP et al. - In a trial to examine the effects of mucin 1 (MUC1) on global gene expression patterns and the potential role of MUC1-induced genes in predicting outcome for breast cancer pts, it was shown that MUC1 regulates cholesterol and fatty acid metabolism, and activation of these pathways in estrogen receptor (ER)+ breast cancers predicts failure of tamoxifen treatment.

Methods

An experimental model of MUC1-induced transformation was developed that has identified the activation of genes involved in cholesterol and fatty acid metabolism.
A 38-gene set of experimentally derived MUC1-induced genes associated with lipid metabolism was applied to analysis of ER+ breast cancer pts treated with tamoxifen.

Results

Results obtained from 2 independent databases demonstrate that pts overexpressing MUC1 and lipid metabolic pathways are at significantly higher risk for death and recurrence/distant metastasis.
These genes were not predictive in untreated pts.
A positive correlation was found between expression of the 38-gene set and ER signaling pathway.

<< Previous
Economic cost of autism in the UK

Next >>
Expression of endoglin (CD105) in cervical cancer